Compare Standard Lithium Ltd (SLI) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Standard Lithium Ltd vs Twist Bioscience Corp — how do they compare? Standard Lithium Ltd trades at $1.58 (market cap $398.07M), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 25.3× Standard Lithium Ltd's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Standard Lithium Ltd for 23 Days and Twist Bioscience Corp for 27 Days on average.
| SLI | TWST | |
|---|---|---|
Market Cap | $398.07M | $10.08B |
Volume | 1,564,155 | 4,229,037 |
Sector | Basic Materials | Health |
52-Week High | $5.65 | $205.00 |
52-Week Low | $1.61 | $25.45 |
Typical Hold Time | 23 Days | 27 Days |
Enterprise Value | $260.98M | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Standard Lithium (SLI) trades at $1.58, down 4.24% today, with a bearish technical signal but bullish oscillators. The company shows negative profitability metrics with ROE at -15.55% and net income of -$48.40M for 2025, though recent quarterly EPS have beaten expectations. Positive developments include progress toward a final investment decision for the South West Arkansas lithium project by end of 2026 and expanded offtake agreements.
The outlook is mixed: analyst consensus is strongly bullish with a $3.83 price target (142% upside), but execution risks remain high as the company transitions to production. Key risks include project delays, funding needs, and negative cash flow from operations. The stock offers high potential reward but requires careful risk assessment given pre-revenue status.
Twist Bioscience (TWST) trades at $152.05, down 2.31% today but remains near recent highs following a significant rally driven by AI partnerships and strong sector interest. The company shows improving revenue growth ($377M in 2025) but continues to post substantial losses (-$78M net income). Technical indicators show mixed signals with bullish overall sentiment but bearish moving averages, while analyst consensus remains positive with 73% buy ratings.
TWST presents a high-risk, high-reward opportunity with strong growth potential through AI-driven drug discovery partnerships but faces significant execution risks amid persistent profitability challenges. The stock's valuation appears stretched given current fundamentals, requiring successful commercialization of pipeline assets to justify premium multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
